Navigation Links
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Date:2/19/2008

- Establishes Plan for Biomarker Study -

MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia. The biomarker study, and additional formulation and manufacturing activities for MEM 3454, will be funded by Roche, under the companies' collaboration for the development of nicotinic alpha-7 receptor agonists.

"This new study will greatly enhance our ability to measure and predict the efficacy of MEM 3454 and other compounds in the nicotinic alpha-7 receptor program," said Stephen Murray, MD, Ph.D, Chief Medical Officer of Memory Pharmaceuticals Corp. "The study should be underway this summer with data available by early 2009. The biomarker data, together with the results of our ongoing Phase 2a study in CIAS, will help with the design of later-stage trials in schizophrenia."

The biomarker study will enroll approximately 12 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive MEM 3454 and placebo in a 5-way cross-over design. Each subject will participate in 5 treatment periods. During each period, subjects will receive single doses of 1 mg, 5 mg, 15 mg, or 50 mg of MEM 3454 or placebo, with a 4-day wash-out period between each treatment period. The primary objective of the trial is to study P50 sensory gating and mismatch negativity as potential efficacy biomarkers for nicotinic alpha-7 agonists, such as MEM 3454, in schizophrenia. P50 sensory gating and mismatch nega
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... BOSTON, Jan. 27, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) ... the three months ended December 31, 2010 in the amount ... a result of instrument sales to over fifty Hospitals, Clinics, ... States. Solos looks towards continued growth in 2011 ...
... /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. ... the "Company"), a leading developer, manufacturer and marketer of ... and other health and nutritional products in the People,s ... products, Ranitidine Hydrochloride Capsule, has been added to the ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 2Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List 3
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... This news release is available in French . ... different factors in 14 year old teens, including brain structure ... with 70% accuracy who will go on to develop binge ... lack of conscientiousness, and other variables such as life events ... likelihood of binge drinking. Whether or not the child ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
Breaking Medicine News(10 mins):Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Study finds kidney donation safe for healthy older adults 2
... In this season of giving and sharing, St.,David,s Community ... $5.15 million in grants to area nonprofit organizations that ... "Especially this year, we ... care for Central Texans," said Earl Maxwell, CEO of ...
... Dec. 16 Globus Medical, Inc., the largest privately ... the appointment of Wendy DiCicco, CPA, as Chief Financial ... of a publicly traded medical device manufacturer to the ... she was the CFO for Kensey Nash Corporation (Nasdaq: ...
... 16 SunTrust Banks, Inc.,(NYSE: STI ... for employers seeking to take control of their ... administrative and financial,components, including a healthcare payment card, ... options, offered,through a single trusted custodial partner. , ...
... January 2009 issue, The Journal of Nuclear Medicine ... , "This change to the publication allows the ... structure and organization of research reports," said Heinrich R. ... of Nuclear Medicine . "Most important and critical, it ...
... The Body By Milk campaign -- famous for,putting white ... up with the,five-time GRAMMY(R)-Award winning and multi-platinum selling artist, Usher, ... the Body By,Milk got noise? music video program. , ... give 20 lucky teens the chance to flex their,creative muscle ...
... 16 December 2008 - The effectiveness of voriconazole in ... study to be featured in the International Journal ... Elsevier. Fungal infections can kill people with weakened immune ... or organ replacement, and the research reinforces earlier findings ...
Cached Medicine News:Health News:$5.15 Million Provided to Support Local Health Care Needs 2Health News:$5.15 Million Provided to Support Local Health Care Needs 3Health News:$5.15 Million Provided to Support Local Health Care Needs 4Health News:Globus Medical Strengthens Executive Team with Appointment of CFO 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 3Health News:Journal of Nuclear Medicine premiers new, full-color design 2Health News:Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity 2Health News:Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity 3Health News:Voriconazole: A highly potent treatment for fungal infections 2
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
Medicine Products: